Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Celanese inks agreement with the Population Council to supply its VitalDose drug delivery platform

The VitalDose Drug Delivery Platform has been used in patient-centric dose forms in women’s health for over two decades

Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants

The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.

Celanese showcases advanced medical materials solutions at Medtec China 2023

elanese now offers Zytel Resin, Hytrel TPC, Crastin PBT and Micromax Electronic Inks and Paste following its 2022 acquisition of the majority of the Mobility & Materials (M&M) business from DuPont

Celanese collaborates with Alessa Therapeutics for the advancement of oncology treatments

The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients

Celanese support the sustained-release drug delivery market

Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions

Celanese announces Grant Award to develop refillable drug delivery solution

Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation

Ovensa and Celanese to collaborate to advance precision drug delivery

Celanese opens drug delivery feasibility lab at Florence, Kentucky site

State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides

Nanoform and Celanese explore ways to enhance drug delivery

Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.